Reckitt Benckiser benefits from heroin addiction treatment
1 min read
The household, health and personal care group Reckitt Benckiser enjoyed a "year of market-beating results" helped by the performance of its patented heroin addiction drug treatment Suboxone.
2010 revenue was up 9% to £8.4 billion while operating profit rose 13% to £2.1 billion.
CEO Bart Becht (pictured) said: "Reckitt Benckiser enjoyed another year of market-beating results, despite declining global market growth," providing evidence that the company's strategy of focusing on its 'powerbrands', continued to deliver results.
He went on: "The progress we have made on the recently introduced and patented-protected Suboxone film is very encouraging. As is well known, our Suboxone tablets can become subject to generic competition at any time, and moving more of our business into the film has been a key priority. At the end of 2010, the Suboxone film had captured a 25% volume share of the U.S. market, well ahead of our ingoing expectations, and at this level it would represent approximately 23% of the total RBP U.S. net revenue.
"For 2011, we are aiming for another year of above industry-average growth."
